Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Creative Labs (CREAF) -- Ignore unavailable to you. Want to Upgrade?

To: relentless who wrote (9175)	1/28/1998 5:19:00 PM
From: Brad Patton	Respond to of 13925

To relentless: Are Research development generally write off during during the acquiring of a company? Or what is written off? So, there earnings did grow then, and not decrease. I thought the eps was decreased, which worried me. How do you find out what is written off? There are two general write-offs you will see when a company acquires another one. The first is for in-process R&D which is usually reduced from earnings in the quarter in which the transaction completes. The second is for goodwill. Goodwill is an accounting concept used to reconcile the difference in the purchasing price vs the book value (or shareholders equity) of a company. Goodwill is amortized over a period of time. Usually the companies press release is the best place to look for these numbers. For example from the Creaf press release: After one-time write-offs -- totaling US$60.3 million -- for in-process technology related to the acquisitions of ENSONIQ, Cambridge SoundWorks and the NetMedia group of OPTi, the results for the second quarter of fiscal 1998 were: On the income sheet you'll notice a line called Write off of acquired in-process technology this is where the 60 million is recorded For a good general discussions of some of these issues check out: fool.com PS. If any of this wrong I'm sure someone on this thread will correct it.

To: relentless who wrote (9175)	1/28/1998 10:15:00 PM
From: Jon Tara	Read Replies (2) \| Respond to of 13925

I beleive that the R&D that was written-off is R&D that will not go forward. This was primarly Ensoniq. I think this tells us something of what CREAF has in mind going forward. I beleive that they bought Ensoniq mainly to put a competitor out of commission, capture a brand name and their customers. I beleive that they will be phasing-out the current Ensoniq products and phasing-in their own PCI products. There have been comments here expressing confusion about what Creative was going to do with two PCI product lines. I think we now know - in this case, Creative bought market share, not technology.